ADPT
Adaptive Biotechnologies Corp
26.50$
+1.5%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Cash Flow
Adaptive Biotechnologies Corp (ADPT) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -6.4 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.1 | -9.1 | -12 | -5.4 | 278 | -16 | -30 | -27 | -32 | -31 | -47 | -40 | -58 | -37 | -43 | -54 | -64 | -47 | -42 | -30 | -59 | -24 | -47 | -27 | -38 | -17 | -27 | -12 | -28 | -12 | -7.1 | 2.1 | -9.5 | -6.4 | -21 | |
| 1.5 | 1.5 | 1.5 | 1.6 | 1.8 | 1.9 | 2.1 | 2.1 | 2.6 | 2.7 | 2.1 | 3.4 | 2.7 | 4.7 | 3.5 | 6.6 | 6.8 | 7.0 | 7.2 | 7.1 | 7.2 | 7.5 | 7.6 | 5.4 | 5.2 | 5.0 | 4.6 | 4.4 | 4.7 | 4.5 | 4.4 | 4.2 | 3.8 | 3.7 | 16 | |
| 3.1 | 2.4 | 2.6 | 3.0 | 3.0 | 3.3 | 3.3 | 3.4 | 4.7 | 6.4 | 6.5 | 7.2 | 8.5 | 11 | 12 | 12 | 13 | 14 | 14 | 14 | 15 | 17 | 15 | 16 | 14 | 13 | 14 | 13 | 12 | 13 | 13 | 13 | 12 | 11 | 49 | |
| 2.9 | 2.1 | 2.2 | – | 2.4 | 4.2 | 1.7 | 2.9 | 4.5 | 5.4 | 8.2 | 11 | 8.5 | 15 | 12 | 12 | 13 | 14 | 14 | 15 | 17 | 18 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 1.9 | -0.2 | -7.0 | 3.6 | 292 | -6.4 | -20 | -11 | -6.7 | -5.0 | -21 | -8.3 | -33 | -5.9 | -6.2 | -12 | -22 | -19 | -19 | -10 | -24 | 0.4 | -19 | -3.5 | -10 | 2.8 | -13 | 3.1 | -16 | -5.3 | -34 | -2.5 | -6.3 | 1.0 | -42 | |
| 0.6 | 1.0 | 2.2 | 2.5 | 3.8 | 1.5 | 3.4 | 2.4 | 3.0 | 2.3 | 4.2 | 9.4 | 16 | 22 | 15 | 9.2 | 3.1 | 5.3 | 5.4 | 2.5 | 2.9 | 3.7 | 2.8 | 1.3 | 1.5 | 1.7 | 0.3 | 0.1 | 1.3 | 0.7 | 0.4 | 0.6 | 0.8 | 1.2 | 3.0 | |
| -37 | 4.7 | 5.1 | 28 | -222 | -45 | -261 | 47 | 143 | 177 | -97 | -340 | 94 | 41 | -21 | 67 | 38 | 4.7 | 58 | -98 | 63 | 37 | 26 | 3.2 | 45 | 5.9 | 5.3 | 22 | 26 | 3.3 | 17 | -8.3 | 9.1 | -43 | -25 | |
| 0.0 | – | – | – | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0 | – | – | 1.3 | 0.1 | 2.0 | 323 | 325 | 5.0 | – | – | – | 14 | 6.3 | 2.9 | 3.3 | 2.7 | 4.0 | 0.8 | 0.3 | 0.7 | – | – | – | – | – | – | – | – | – | – | – | – | -25 | – | |
| 0.0 | – | – | – | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.5 | 0.4 | 0.1 | 0.3 | 0.1 | -1.5 | 320 | 1.7 | 5.0 | 6.3 | 276 | 6.3 | 15 | 6.3 | 2.9 | 3.3 | 2.7 | 4.0 | 126 | 0.0 | 0.7 | 1.5 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 5.5 | 1.6 | 1.7 | 22 | 7.5 | 142 | 173 | |
| -42 | -4.0 | -6.5 | 22 | 56 | -63 | 29 | 22 | 116 | 153 | 132 | -374 | 50 | 11 | -62 | 17 | -24 | -38 | 141 | -128 | 4.5 | 15 | -21 | -24 | 6.2 | -11 | -22 | 9.8 | 2.7 | -7.5 | 12 | 15 | 7.1 | 92 | 127 | |
| -6.7 | -10 | -14 | -7.9 | 274 | -17 | -34 | -29 | -35 | -33 | -51 | -49 | -74 | -59 | -58 | -63 | -68 | -52 | -48 | -33 | -62 | -27 | -49 | -28 | -40 | -19 | -27 | -13 | -30 | -13 | -7.5 | 1.4 | -10 | -7.6 | -24 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.